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ORIGINAL ARTICLE
Paget’s osteosarcoma Ð no cure in sight
PHILLIP J. SHAYLOR, DAVID PEAKE, ROBERT J. GRIMER, SIMON R. CARTER,
ROGER M.TILLMAN & DAVID SPOONER
The Royal Orthopaedic Hospital Oncology Service, Bristol Road South, Birmingham B31 2AP, UK
Abstract
Purpose Paget’s osteosarcoma has a fearful reputation with a quoted survival of at best 5% at 5 years.We therefore reviewed
our experience of 26 patients treated over the last 25 years using modern staging and limb salvage techniques to see if there
had been any improvement in survival.
Subjects: We identi® ed 26 patients on the Royal Orthopaedic Hospital Oncological database with a diagnosis of sarcoma
secondary to Paget’s disease.
Results:The survival rate was 53% at 1 year, 25% at 2 years and no patient survived for 5 years.The median survival was 21
months for those treated with curative intent and 7 months for those treated palliatively. Four of the ® ve patients treated with
limb-sparing surgery developed local recurrence between 5 and 12 months, the ® fth died at 14 months.There was no differ-
ence in survival between amputation and limb salvage.
Discussion:The development of sarcomatous change in Paget’s disease is well recognised. It represents an important segment
of primary bone tumours in patients over 40 years of age.The prognosis is appalling. Indeed only 15 of 368 cases (4%) from
a number of historical series have survived more than 5 years. Our results are similarly disappointing with no survivors at 5
years despite modern methods of management of bone tumours. While there is no difference in local recurrence rates or
survival between limb reconstruction and limb ablation the poor prognosis for both means that neither can be recommended
at present. Sarcomatous change in Pagetoid bone should therefore be regarded as a different disease to primary osteosar-
coma. It remains an incurable disease with a poor prognosis.
Introduction
The development of sarcomatous change in Paget’s
disease of the bone is well recognised. Indeed ® ve of
the ® rst 23 cases that were reported by Paget
developed sarcoma.
The incidence of this complication is not known
but has been reported to be between 0.7 and 15%
1± 4
Previous reports have demonstrated the very poor
prognosis of Paget’s osteosarcoma with very few
patients surviving 5 years.
5± 10
We therefore reviewed our experience of 26 patients
treated over the last 25 years using modern staging
and limb salvage surgery to see if there had been any
improvement in the prognosis.
Method
We identi® ed 26 patients whom had been referred for
advice or treatment on the Royal Orthopaedic
Hospital Oncological database with a diagnosis of
sarcoma secondary to Paget’s disease. Eighteen
patients were male and eight female.Their mean age
was 70 years (range 58± 89 years). Seventeen were
stage 2b and 6 stage 3. The most common locations
for the lesion were humerus and pelvis with eight
cases each.There were seven cases involving the femur
and one case involving each of the tibia, ulna and
skull. Histologically 22 of the cases had classical
Paget’s osteosarcoma while the remaining four had a
spindle cell sarcoma with no visible osteoid.
Treatment
Eleven of the 26 patients underwent surgical resec-
tion with six having primary amputation and ® ve
having limb-sparing surgery with endoprosthetic
replacement. In only 2 patients was it considered
appropriate to use chemotherapy. Neither patient was
considered to have bene® ted from chemotherapy. Five
patients were treated with radiotherapy while 10
patients had palliative treatment only.
Results
The survival rate was 53% at 1 year, 25% at 2 years
and no patient survived for 5 years, all patients’ dying
of metastatic disease. The median survival was 21
months for those treated with curative intent and 7
months for those treated palliatively. Four of the ® ve
patients treated with limb sparing surgery developed
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died at 14 months.There was no difference in survival
between amputation and limb salvage (Fig. 1).
Discussion
The development of sarcomatous change in Paget’s
disease is well recognised. It represents an important
segment of primary bone tumours in patients over 40
years of age.The prognosis is appalling. Indeed only
15 of 368 cases (4%) from a number of historical
series have survived more than 5 years.
Our series is comparable to those of Greditzer,
Scharjowicz and Smith
4± 6 with a similar sex and age
distribution. The site of disease is similarly mainly
pelvis, femur and humerus. Histologically osteosarco-
mata are the most common type of sarcomatous
change seen.
There have been many different approaches to
treatment. Greditzer
6 performed ablative surgery in
18 cases with adjuvant chemotherapy and
radiotherapy in six of theses but only had three
survivors for 5 years. Huvos and Smith
4,7 have used
adjuvant chemotherapy from 1974 but have a survival
of six from 150 patients between their two series.
Schajowicz
5 in his review of the Latin± American
registry of Bone Tumours had only a 1.5% (one of
62) 5-year survival
Our results are similarly disappointing with no
survivors at 5 years despite modern methods of
management of bone tumours.There is no difference
in local recurrence rates or survival between limb
reconstruction and limb ablation and therefore neither
can be considered curative.The decision as to which
method of surgery should be offered for the individual
patient will be based on which is felt to give the best
palliation and the best function for that individual.
Sarcomatous change in Pagetoid bone should
therefore be regarded as a different disease to primary
osteosarcoma. It remains an incurable disease with a
poor prognosis.
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Figure 1. Sarcomas complicating Paget’s disease of bone.
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